J&J Exec On COVID-19 Vaccine: Moving At High Speed But No Safety Compromises
'Different Way Of Working'
Executive Summary
J&J executive emphasizes that fast-tracked development of COVID-19 vaccines does not come with any corners cut around safety. Indian partner Biological E also outlines the complexities in manufacturing and believes that the candidates from J&J, AstraZeneca and others will be more suitable in profile and price terms to contain the pandemic globally.
You may also be interested in...
Watch This Space: Reliance Advances Protein-Based COVID-19 Vaccine
Reliance Life Sciences, part of India’s largest private sector enterprise with a growing engagement in healthcare, is progressing an early-stage COVID-19 vaccine. A top executive underscores the potential to manufacture at scale and provide the protein-based candidate at a competitive price.
Expanded Distribution For COVID Vaccines Will Boost Options – And Logistical Complications
Operation Warp Speed officials eye the Moderna vaccine and upcoming one-shot Janssen product to widen the immunization campaign’s reach, but more products also could bring more problems.
Coronavirus Update: SK Bioscience, Biological E, DongWha And Celltrion Report Progress
SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.